Global Gene Therapy On Cardiovascular Disease Market Growth (Status and Outlook) 2025-2031

The global Gene Therapy On Cardiovascular Disease market size is predicted to grow from US$ 573 million in 2025 to US$ 30920 million in 2031; it is expected to grow at a CAGR of 94.4% from 2025 to 2031.

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.

Market Driver: The increasing prevalence of cardiovascular diseases (CVDs) worldwide is a major driver for the gene therapy market in this area. As traditional treatments, such as surgery, medications, and lifestyle changes, sometimes fail to offer long-term solutions, gene therapy presents a promising alternative. By targeting the root causes of CVDs at the genetic level, gene therapy offers the potential for more effective and durable treatments. Advancements in gene editing technologies, such as CRISPR, have further accelerated the development of gene therapies for cardiovascular diseases, allowing for precise modification of genes that regulate heart function, blood vessel health, and inflammation. This technological progress, combined with the growing demand for personalized and innovative treatments, is driving the market forward.Market Challenge: Despite its potential, the gene therapy market for cardiovascular diseases faces several challenges, including high development costs and the complexity of clinical trials. Developing safe and effective gene therapies requires significant investment in research and long-term testing, which can delay the availability of these therapies to patients. Additionally, regulatory approval for gene therapies can be slow and uncertain, creating barriers to rapid commercialization. Moreover, there are concerns regarding the long-term safety and potential unintended genetic consequences of modifying human DNA, which may limit widespread adoption. The complexity of delivering gene therapies to the cardiovascular system, such as targeting specific cells or tissues without causing adverse effects, remains a significant technical challenge.

Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%.

LPI (LP Information)' newest research report, the “Gene Therapy On Cardiovascular Disease Industry Forecast” looks at past sales and reviews total world Gene Therapy On Cardiovascular Disease sales in 2024, providing a comprehensive analysis by region and market sector of projected Gene Therapy On Cardiovascular Disease sales for 2025 through 2031. With Gene Therapy On Cardiovascular Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy On Cardiovascular Disease industry.

This Insight Report provides a comprehensive analysis of the global Gene Therapy On Cardiovascular Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gene Therapy On Cardiovascular Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy On Cardiovascular Disease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy On Cardiovascular Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy On Cardiovascular Disease.

This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy On Cardiovascular Disease market by product type, application, key players and key regions and countries.

Segmentation by Type:
Viral Gene Therapy
Non-Viral Gene Therapy

Segmentation by Application:
Heart Disease
Vascular Disease

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Renovacor
Gene Biotherapeutics
AskBio
Human Stem Cells Institute
Novartis
Biogen
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.